JPS58128310A - Skin conditioner - Google Patents
Skin conditionerInfo
- Publication number
- JPS58128310A JPS58128310A JP1086982A JP1086982A JPS58128310A JP S58128310 A JPS58128310 A JP S58128310A JP 1086982 A JP1086982 A JP 1086982A JP 1086982 A JP1086982 A JP 1086982A JP S58128310 A JPS58128310 A JP S58128310A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- pantethine
- parts
- lipid metabolism
- abnormality
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims abstract description 27
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims abstract description 27
- 229960000903 pantethine Drugs 0.000 claims abstract description 27
- 235000008975 pantethine Nutrition 0.000 claims abstract description 27
- 239000011581 pantethine Substances 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000037356 lipid metabolism Effects 0.000 abstract description 8
- 230000005856 abnormality Effects 0.000 abstract description 6
- 238000000354 decomposition reaction Methods 0.000 abstract description 3
- 238000002845 discoloration Methods 0.000 abstract description 2
- 230000036548 skin texture Effects 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000037303 wrinkles Effects 0.000 abstract description 2
- 206010034018 Parosmia Diseases 0.000 abstract 1
- 230000009849 deactivation Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000007788 roughening Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000006981 Skin Abnormalities Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 208000000069 hyperpigmentation Diseases 0.000 description 3
- 230000003810 hyperpigmentation Effects 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は、パンテチンを含有する化粧用又は医薬用の肌
質改善剤に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a cosmetic or pharmaceutical skin quality improving agent containing pantethine.
パンテチンはパンテティンと共に生体内にその存在が認
められ、還元されてパンテティンとしてアセチル補酵素
、アセデルキャリヤープロティン等の構成成分となり、
炭水化物代謝、脂肪酸分解、合成等に関与するなどの広
い生理作用を有することが知られている。このパンテチ
ンについては最近その薬理効果が注目され、脂肪代謝に
及ぼす影響や動脈硬化の予防あるいは修復作用が解明さ
れつつある現状にあるが、皮膚に外用薬として応用され
た例は知られていな℃飄。Pantethine is found in living organisms along with pantethine, and is reduced to form pantethine, a component of acetyl coenzyme, acedel carrier protein, etc.
It is known to have a wide range of physiological actions, including involvement in carbohydrate metabolism, fatty acid decomposition, synthesis, etc. Pantethine has recently attracted attention for its pharmacological effects, and its effects on fat metabolism and prevention and repair effects on arteriosclerosis are currently being elucidated, but there are no known examples of it being applied to the skin as an external drug. Air.
皮膚での異常特に脂質代謝の異常は、一般に皮脂腺にお
ける機能の障害により生ずるものと考えられ、外観的に
は肌荒れ、荒れ症などのような乾燥性の症状として現わ
れたり、逆に皮脂分泌過多に伴うにきびの生成などの症
状がみられる。そのほか肌質の異常としては色素沈着症
例えばしみ、そばかす、色黒などの症状もみられる。Abnormalities in the skin, particularly abnormalities in lipid metabolism, are generally thought to be caused by dysfunction in the sebaceous glands, and may appear as dry symptoms such as rough skin or rashes, or conversely, may be caused by excessive sebum secretion. Symptoms such as acne formation are seen. Other skin abnormalities include hyperpigmentation, such as age spots, freckles, and dark skin.
肌荒れや荒れ症を正常化するため、これまで胎盤製剤や
ビタミン類が主に用いられていたが、本質的な意味での
充分な効果は得られていない。Until now, placenta preparations and vitamins have been mainly used to normalize rough skin and rough skin, but they have not been effective in a substantial sense.
そのほか男性ホルモンを用いる方法もあるが、これを過
剰に使用すると皮脂分泌の均衡を変化させ、かえって正
常な代謝を妨げるおそれがある。また皮脂分泌の過多に
対しては女性ホルモンの使用が考えられるが、男性ホル
モンとは反対に乾燥性の症状が過度に顕在化する傾向が
あり、いずれも満足できるものではない。Other methods include the use of male hormones, but excessive use of these can alter the balance of sebum secretion and may even interfere with normal metabolism. In addition, the use of female hormones can be considered to treat excessive sebum secretion, but unlike male hormones, dryness symptoms tend to become excessively obvious, so neither method is satisfactory.
本発明者らは、パンテチンの外用」二の作用について鋭
意研究した結果、パンテチンが、皮膚内における脂質代
謝を症状の態様に応じて調節することができ、肌荒れ、
荒れ症、皮脂分泌の過多などの脂質代謝の異常に基づ(
変化の改善ならびに、色素沈着症などの肌質異常に効果
のあることを見出して、本発明を完成した。As a result of intensive research into the effects of external use of pantethine, the present inventors found that pantethine can regulate lipid metabolism in the skin according to the symptoms, and has shown that pantethine can regulate skin roughness,
Based on abnormalities in lipid metabolism such as rough skin and excessive sebum secretion (
The present invention was completed after discovering that it is effective for improving skin changes and treating skin abnormalities such as hyperpigmentation.
本発明の脂質改善剤の有効成分であるパンテチンは下記
式で示される化合物であり、パンテティンの2分子が未
満のメルカプト基相互の間でジスルフィド結合して生ず
る物質である。これを得る方法としては、例え“ばパン
トテン酸を出発物質とする合成法、コエンチームAを単
段[(する方法その他種々の方法が知られている(特公
昭41−2896号及び特公昭44−3324号各公報
参照)。Pantethine, which is an active ingredient of the lipid improving agent of the present invention, is a compound represented by the following formula, and is a substance produced by disulfide bonding between two molecules of pantethine and less than 2 mercapto groups. As methods for obtaining this, for example, a synthetic method using pantothenic acid as a starting material, a method in which coenzyme A is synthesized in a single stage, and various other methods are known. (Refer to each publication No. 3324).
本発明によれば、パンテチンは賦形剤、希釈剤、補助剤
等と共にクリーム、ローション、粉末剤、軟膏などの形
で用いられる。これらの化粧料及び医薬製剤は常法によ
り製造できる。According to the invention, pantethine is used in the form of creams, lotions, powders, ointments, etc. together with excipients, diluents, adjuvants, etc. These cosmetics and pharmaceutical preparations can be manufactured by conventional methods.
本発明の肌質改善剤に含有されるパンテチンの含有量は
通常0.01〜5重量%、好ましくは0.1〜1重量%
である。0.01重量%より少ない量では充分な効果が
得られない。また5重量%を超える量では効果の増強が
なく不経済である。The content of pantethine contained in the skin quality improving agent of the present invention is usually 0.01 to 5% by weight, preferably 0.1 to 1% by weight.
It is. If the amount is less than 0.01% by weight, sufficient effects cannot be obtained. Moreover, if the amount exceeds 5% by weight, the effect will not be enhanced and it will be uneconomical.
本発明の肌質改善剤の有効成分であるパンテチンは、熱
及び光に対して極めて安定であり、製剤とした場合も変
色、変臭、分解失活などの経時変化を起こさず、また各
種外用基剤に対して容易に配合することができる点で極
めて有利である。さらに毒性や皮膚障害の心配は全くな
(、安全に用いることができる。Pantethine, the active ingredient of the skin quality improving agent of the present invention, is extremely stable against heat and light, and does not undergo changes over time such as discoloration, odor, or decomposition and inactivation even when made into a preparation. It is extremely advantageous in that it can be easily blended into the base. Furthermore, there is no concern about toxicity or skin damage (it can be used safely).
本発明の肌質改・養剤は、脂質代謝の改善に効果のある
といわれているビタミン類やホルモン類を用いたものよ
りはるかに著効を有する。本 4−
剤は外用剤として皮膚に直接塗布することにより、肌荒
れ、荒れ症などの脂質代謝の異常を改善するだけでなく
、小じわ、肌のきめ、はり等の改善にも効果がみられる
。The skin quality improving/nourishing agent of the present invention is far more effective than those using vitamins and hormones, which are said to be effective in improving lipid metabolism. When applied directly to the skin as an external preparation, this agent not only improves abnormalities in lipid metabolism such as rough skin and chapped skin, but is also effective in improving fine wrinkles, skin texture, firmness, etc.
本発明の肌質改善剤を用い脂質代謝の改善及び色素沈着
症の治療効果を検討し、あわせて市販のビタミンE含有
クリームと比較した。適用方法としては、実施例1〜乙
の製品を、肌荒れ、荒れ症、にきび、しみなどの肌質異
常を呈する20〜40才の女性18名の顔面患部に1日
朝及び就寝前の2回ずつ6力月間継続して塗布し、適用
患部の治療状態を観察して報告させた。その結果を第1
表に示す。本発明の肌質改善剤は市販品より著しく優れ
ていることが知られる。The effects of improving lipid metabolism and treating hyperpigmentation using the skin quality improving agent of the present invention were investigated, and compared with a commercially available cream containing vitamin E. The method of application was to apply the products of Examples 1 to B to the affected areas of the face of 18 women aged 20 to 40 with skin abnormalities such as rough skin, rough skin, acne, and age spots twice a day, once in the morning and before going to bed. The treatment was applied continuously for 6 months, and the treatment status of the affected area was observed and reported. The result is the first
Shown in the table. It is known that the skin quality improving agent of the present invention is significantly superior to commercially available products.
特にかなり悪化した症状を呈する4名の女性に対し、本
発明の肌質改善剤は優れた効果を示した。In particular, the skin quality improving agent of the present invention showed excellent effects on four women with considerably worsened symptoms.
(A)改善程度は、自己判定して 1:変化なし 2:やや改善されたような気がする 6:やや改善された 4:明らかに改善された の各段階に区別し、その平均値を表中に示した。(A) The degree of improvement is self-assessed. 1: No change 2: I feel like it has improved somewhat. 6: Slightly improved 4: Clearly improved The average value is shown in the table.
(B)市販品との比較は、半顔比較法を用い、6:本則
が極めて優れている
2:本則がやや優れている
1:本則と同等
の各段階に区別し、その平均値を表中に示した。(B) Comparisons with commercially available products are made using the half-face comparison method. 6: The main rule is extremely good. 2: The main rule is slightly better. 1: Equivalent to the main rule. The average value is shown. Shown inside.
第 1 表 下記実施例中の部は重量を意味する。Table 1 Parts in the examples below refer to weight.
実施例1(皮膚用クリーム)
FA>スクアラン 10.0部ワセリン
10.0部
蜜ろう 6.0部
マイクロワックス 90部鯨ろう
6,0部イソプロピルミリステート
12.o部ソルビタンモノステアレート5.0部
パラオキシ安息香酸メチル 0.1部(B)1
.3−ブタンジオール 10.0部パンテチン
o、i部
蒸留水 62.8部
(C)香料 0.5部
油性成分(A)及び水性成分CB)を別個に80℃に加
熱して溶解し、両者を混合して乳化する。次いで冷却し
ながら香料(C)を加え、60℃まで冷却して製品とす
る。Example 1 (skin cream) FA>Squalane 10.0 parts Vaseline
10.0 parts beeswax 6.0 parts micro wax 90 parts whale wax
6,0 parts isopropyl myristate
12. Part o Sorbitan monostearate 5.0 parts Methyl paraoxybenzoate 0.1 part (B) 1
.. 3-Butanediol 10.0 parts Pantethine
o, part i Distilled water 62.8 parts (C) Perfume 0.5 parts The oil component (A) and the aqueous component CB) are separately heated to 80° C. and dissolved, and both are mixed and emulsified. Next, fragrance (C) is added while cooling, and the product is cooled to 60°C.
実施例2(皮膚用クリーム)
FA)セタノール 6,5部鯨ろう
6.0部
ラノリン 2.0部
流動パラフィン 20.0部
抗酸化剤 0.1部
ソルビタンモノオレート2.0部
パンテチン 0.5部
CB)グリセリン 10.0部蒸留水
52.0部
(C)香料 0.4部
(A)及びCB)を別個に80℃に加熱して溶解し、両
者を混合乳化1.、冷却して香料を加え、均一に分散し
て製品とする。Example 2 (skin cream) FA) Cetanol 6.5 parts spermaceti
6.0 parts Lanolin 2.0 parts Liquid paraffin 20.0 parts Antioxidant 0.1 part Sorbitan monooleate 2.0 parts Pantethine 0.5 parts CB) Glycerin 10.0 parts Distilled water
52.0 parts (C) Fragrance 0.4 parts (A) and CB) were separately heated to 80°C and dissolved, and both were mixed and emulsified. , cool, add fragrance, and uniformly disperse to form a product.
7 一
実施例6(皮膚用パウダー)
(A)タルク 95部亜鉛華
。部
ステアリン酸亜鉛 2部
(B)パンテチン 1部(C)香料
適量
パンテチン(B)を溶媒に溶解し、これを(A)の粉体
成分によく混合分散したのち、溶媒を留去し、香料(C
)を加え、次いで乾燥して製品とする。7 Example 6 (Skin powder) (A) Talc 95 parts Zinc white
. Part Zinc stearate 2 parts (B) Pantethine 1 part (C) Fragrance
After dissolving an appropriate amount of pantethine (B) in a solvent and thoroughly mixing and dispersing it in the powder component of (A), the solvent was distilled off and the fragrance (C) was dissolved.
) and then dried to form a product.
実施例4(アクネ用ローション)
1−メントール 0.05部プロピレングリ
コール 5.0部パンテチン
0.5部
アルコール 15.0部
香料 0.5部
8−
前記の成分に蒸留水を加えて全量100部とする。Example 4 (lotion for acne) 1-Menthol 0.05 parts Propylene glycol 5.0 parts Pantethine
0.5 parts Alcohol 15.0 parts Fragrance 0.5 parts 8- Add distilled water to the above ingredients to make a total amount of 100 parts.
実施例5(皮膚用軟膏)
(A)パンテチン 1.0部イソプロピ
ルミリステート 10.0部セタノール
10.0部
カーボワックス 5.0部(B)流動パラ
フィン 59,0部パラフィンワックス
5.0部(A)成分を加温溶解して均一となし、
これに(B)成分の混合物を加え、冷却したのち混合し
て製品とする。Example 5 (skin ointment) (A) Pantethine 1.0 parts isopropyl myristate 10.0 parts cetanol
10.0 parts Carbowax 5.0 parts (B) Liquid paraffin 59.0 parts Paraffin wax
5.0 parts (A) component is dissolved by heating to make it homogeneous,
A mixture of component (B) is added to this, and after cooling, the mixture is mixed to form a product.
実施例6(皮膚用軟膏)
(A)鯨ろう 12.5部白ろう
12.0部
流動パラフィン 60.0部
ワセリン 26.0部
パンテチン 2.0部
(B)ホウ酸ナトリウム 0.5部蒸留水
17.0部
(A)成分を70〜80℃に加温して溶解したのち、(
B)成分を徐々に添加混合し、30℃以下になるまで冷
却して製品とする。Example 6 (skin ointment) (A) Sperm wax 12.5 parts White wax
12.0 parts Liquid paraffin 60.0 parts Vaseline 26.0 parts Pantethine 2.0 parts (B) Sodium borate 0.5 parts Distilled water
After heating and dissolving 17.0 parts (A) component at 70 to 80°C, (
B) Ingredients are gradually added and mixed, and the mixture is cooled to 30° C. or lower to form a product.
試験例
パンテチン水溶液及びビタミンC水溶液の熱、光及び経
時変化に対する安定性試験を行った。Test Example Stability tests of pantethine aqueous solution and vitamin C aqueous solution against heat, light, and changes over time were conducted.
試験方法は下記(a)〜(C)のとおりで、試料はパン
テチン及びビタミンC1’X+水溶液(0,1M燐酸緩
衝液を用い、必要に応じ0.1Nカセイソーダと0.1
N塩酸で調整した)を用いた。The test method is as follows (a) to (C), and the sample is pantethine and vitamin C1'
(adjusted with N-hydrochloric acid) was used.
(a)熱安定性=100℃で3時間放置(b)光安定性
:太陽光を3日間照射
(C)経時安定性=40℃で3か月装置その結果を第2
表に示す。パンテチンは、すべての点でビタミンCより
も安定性に優れ、特に皮膚表面に必要とされる弱酸性に
おいて有利に使用でき、製剤としてもその効果が期待さ
れる。(a) Thermal stability = left at 100°C for 3 hours (b) Photostability: irradiated with sunlight for 3 days (C) Aging stability = 3 months at 40°C
Shown in the table. Pantethine has better stability than vitamin C in all respects, and can be advantageously used especially in the weak acidity required for the skin surface, and is expected to be effective as a preparation.
第 2 表
残存率二 〇:90%以上○:8o〜9o%Δ:60〜
80%×:6o%未満
変 臭ニー:なし 士:ややあり +:あり出願人 第
一製薬株式会社lA1名
代理人 弁理士率 林 正 雄Table 2 Residual rate 2 〇: 90% or more ○: 8o~9o%Δ: 60~
80%×: Less than 6o% change Odor: None Professional: Slightly +: Yes Applicant Daiichi Pharmaceutical Co., Ltd. 1A representative Patent attorney ratio Masao Hayashi
Claims (1)
肌質改善剤。A skin quality improving agent characterized by containing pantethine as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1086982A JPS58128310A (en) | 1982-01-28 | 1982-01-28 | Skin conditioner |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1086982A JPS58128310A (en) | 1982-01-28 | 1982-01-28 | Skin conditioner |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS58128310A true JPS58128310A (en) | 1983-07-30 |
Family
ID=11762342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1086982A Pending JPS58128310A (en) | 1982-01-28 | 1982-01-28 | Skin conditioner |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS58128310A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58134023A (en) * | 1982-02-04 | 1983-08-10 | Dai Ichi Seiyaku Co Ltd | Remedy for acne vulgaris |
JPS58134022A (en) * | 1982-02-04 | 1983-08-10 | Dai Ichi Seiyaku Co Ltd | Remedy for hyperpigmentation |
JP2007269786A (en) * | 2006-03-09 | 2007-10-18 | Daiichi Sankyo Healthcare Co Ltd | Pantethine-containing oral liquid preparation |
WO2011030727A1 (en) | 2009-09-11 | 2011-03-17 | 第一ファインケミカル株式会社 | External preparation containing pantethine phosphate ester |
JP2014210762A (en) * | 2013-04-03 | 2014-11-13 | 相互薬工株式会社 | Sebum secretion inhibitor |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3285818A (en) * | 1964-05-07 | 1966-11-15 | Dauchi Seiyaku Kabushiki Kaish | Hair and skin compositions containing pantethine |
JPS5673012A (en) * | 1979-11-20 | 1981-06-17 | Pola Chem Ind Inc | Beautifying cosmetic |
JPS5735511A (en) * | 1980-08-12 | 1982-02-26 | Sogo Yatsukou Kk | Dermatic medicine for external application |
-
1982
- 1982-01-28 JP JP1086982A patent/JPS58128310A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3285818A (en) * | 1964-05-07 | 1966-11-15 | Dauchi Seiyaku Kabushiki Kaish | Hair and skin compositions containing pantethine |
JPS5673012A (en) * | 1979-11-20 | 1981-06-17 | Pola Chem Ind Inc | Beautifying cosmetic |
JPS5735511A (en) * | 1980-08-12 | 1982-02-26 | Sogo Yatsukou Kk | Dermatic medicine for external application |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58134023A (en) * | 1982-02-04 | 1983-08-10 | Dai Ichi Seiyaku Co Ltd | Remedy for acne vulgaris |
JPS58134022A (en) * | 1982-02-04 | 1983-08-10 | Dai Ichi Seiyaku Co Ltd | Remedy for hyperpigmentation |
JP2007269786A (en) * | 2006-03-09 | 2007-10-18 | Daiichi Sankyo Healthcare Co Ltd | Pantethine-containing oral liquid preparation |
WO2011030727A1 (en) | 2009-09-11 | 2011-03-17 | 第一ファインケミカル株式会社 | External preparation containing pantethine phosphate ester |
JP2014210762A (en) * | 2013-04-03 | 2014-11-13 | 相互薬工株式会社 | Sebum secretion inhibitor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1078738A (en) | Artificial skin darkening compositions | |
JPS63192703A (en) | External agent for skin | |
EP0440058B1 (en) | Cosmetic composition | |
JP2000327552A (en) | Skin preparation for external use | |
WO2001085156A1 (en) | Dermal compositions containing coenzyme q as the active ingredient | |
EP0633763B1 (en) | Cosmetical or pharmaceutical compositions comprising deacylated glycerophospholipids for topical use | |
JPS63192705A (en) | External agent for skin | |
JPS61260008A (en) | Cosmetic composition | |
US20030143252A1 (en) | Inorganic/organic complexes for reducing skin irritation | |
JPS60112708A (en) | Humectant for skin | |
CA1142854A (en) | Method and compositions for the treatment of seborrhea | |
JPS58128310A (en) | Skin conditioner | |
US6977081B1 (en) | Facial cream composition containing allantoin | |
JPH0532556A (en) | Skin agent for external use | |
JPS6092204A (en) | Cosmetic | |
JP2000344697A (en) | Long-chain branched alcohol and cosmetic and external preparation produced by using the alcohol | |
JP2781982B2 (en) | External preparation for skin | |
JP2004107269A (en) | Carbonylation inhibiting agent for protein, skin care preparation for external use, and method | |
JPS62249907A (en) | Cosmetic | |
EP0640581A1 (en) | Endermic nutrient material and cosmetic composition containing the same | |
JPH07285846A (en) | Promoter for production of collagen and skin cosmetic containing the same blended therein | |
JPH0570333A (en) | Skin medicine for external use | |
JPS60116616A (en) | Cosmetic | |
KR100262176B1 (en) | A stick type lip-care compositions containing retinoid | |
KR20010050016A (en) | Composition for external use |